November 2021
Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01.
Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. A formulation was developed for delivery of NI01 to the nasal cavity and this was shown to retain antimicrobial efficacy, including following accelerated stability experiments.
Formulated NI01 was then evaluated for safety and tolerability in a 14-day model with twice daily dosing at three concentrations and a full panel of clinical observations was conducted. In all investigations, there were no adverse effects observed and it was concluded that NI01 was well tolerated in-life. These findings support the onwards progression of NI01 towards human trials demonstrating that it is safe, stable and efficacious.
